Thirty years on one question: what is it worth?

I've spent my career on one question: what an asset is worth, when to partner it, and what terms to accept.

Founder Story

A Practice Built
to Close a Gap

A Practice Built to Close a Gap

The methods that transformed decision-making inside big pharma never reached the companies that needed them most: emerging biotechs, where capital arrives in discrete events, where there's no in-house forecasting group, and where one partnering decision can determine the company's future.

Every engagement is led personally by Michael, supported by a hand-picked bench of senior life-sciences specialists assembled to fit the assignment.

In the years since, the firm has served more than 100 clients, from venture-backed startups to mid-cap public companies, across biotech, pharma, medical devices, and diagnostics.

What began at Strategic Decisions Group has evolved into a probability-adjusted valuation and deal-economics practice grounded in real transactions, not theory.

Founded in

2003

Rooted in

Menlo Park, CA

Values

Our principles guide every engagement

Evidence Over Assumption

Probability-adjusted analysis, not guesswork or gut feel.

Real Data Over Public Figures

Deal terms benchmarked against unredacted transactions.

Direct, Not Delegated

Michael leads every engagement personally, no junior handoffs.

100+

Clients served

100+

Clients served

100+

Clients served

4

Life-sciences sectors

4

Life-sciences sectors

4

Life-sciences sectors

20+

Transactions closed

20+

Transactions closed

20+

Transactions closed

Philosophy

We Make the Numbers Defensible

Most companies don't need another opinion, they need a number that holds up: to a board, to an investor, to the other side of the table.

Our approach pairs probability-adjusted analysis with real, unredacted deal data, so every recommendation is one you can defend, not just believe.

GLOBAL Clients

Trusted by leaders, from venture-backed startups to mid-cap public companies.

Out-Licensing Advisory

Pfizer Logo

In-Licensing Advisory

Genentech Logo

Portfolio & Transaction Advisory

Seagen logo

Strategic Advisory

Catalent logo

Portfolio Prioritization

Teva logo

Corporate Strategy

Anacor Pharmaceuticals logo

Portfolio Prioritization

Jazz Pharmaceuticals logo

Portfolio Prioritization

Nektar Therapeutics

Portfolio & Divestment Strategy

Geron

Transaction Advisory

Ardelyx

Portfolio & Transaction Advisory

Principa Biopharma

Valuation & Transaction Advisory

Hyperion Therapeutics

Questions & answers

Frequently
Asked Questions

How do I know which service is the best fit for my situation?

Most clients don't arrive asking for a service; they arrive with a decision. A partnering offer on the table. A portfolio that outruns the cash. A board that wants a number it can defend. Tell us what you're deciding and when, and we'll tell you what the work should be. If the answer is a two-week valuation rather than a three-month strategy engagement, we'll say so.

What does the typical engagement timeline look like?

Who actually does the work?

Can you run a transaction for us?

How do you benchmark deal terms?

Do you work with medtech and diagnostics companies, or only therapeutics?